Iradimed Price To Sales vs. Shares Outstanding

IRMD Stock  USD 52.63  1.80  3.31%   
Based on the measurements of profitability obtained from Iradimed's financial statements, Iradimed Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Iradimed's ability to earn profits and add value for shareholders.

Iradimed Price To Sales Ratio

9.61

At present, Iradimed's EV To Sales is projected to drop slightly based on the last few years of reporting. The current year's Price Sales Ratio is expected to grow to 9.61, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.22. At present, Iradimed's Operating Income is projected to increase significantly based on the last few years of reporting. The current year's Income Before Tax is expected to grow to about 22.8 M, whereas Change To Netincome is forecasted to decline to about 1.8 M.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.765
Significantly Down
Pretty Stable
Net Profit Margin0.140.2622
Way Down
Slightly volatile
Return On Assets0.150.1866
Significantly Down
Slightly volatile
Return On Equity0.20.2407
Significantly Down
Slightly volatile
For Iradimed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Iradimed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Iradimed Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Iradimed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Iradimed Co over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0)
Dividend Share
0.45
Earnings Share
1.46
Revenue Per Share
5.635
Quarterly Revenue Growth
0.11
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Iradimed Shares Outstanding vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Iradimed's current stock value. Our valuation model uses many indicators to compare Iradimed value to that of its competitors to determine the firm's financial worth.
Iradimed Co is rated second overall in price to sales category among its peers. It is rated below average in shares outstanding category among its peers creating about  1,354,835  of Shares Outstanding per Price To Sales. At present, Iradimed's Price To Sales Ratio is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Iradimed by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Iradimed Shares Outstanding vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Iradimed

P/S

 = 

MV Per Share

Revenue Per Share

 = 
9.35 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Iradimed

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
12.67 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Iradimed Shares Outstanding Comparison

Iradimed is currently under evaluation in shares outstanding category among its peers.

Iradimed Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Iradimed, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Iradimed will eventually generate negative long term returns. The profitability progress is the general direction of Iradimed's change in net profit over the period of time. It can combine multiple indicators of Iradimed, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income19.6 K20.5 K
Operating Income20 M21 M
Income Before Tax21.7 M22.8 M
Total Other Income Expense Net1.7 M1.8 M
Net Income Applicable To Common Shares14.8 M15.5 M
Net Income17.2 M18.1 M
Income Tax Expense4.5 M4.8 M
Net Income From Continuing Ops16.3 M17.1 M
Non Operating Income Net Other636.1 K667.9 K
Interest Income1.9 MM
Net Interest Income1.9 MM
Change To Netincome1.8 M1.8 M
Net Income Per Share 1.36  1.43 
Income Quality 0.78  1.46 
Net Income Per E B T 0.79  0.56 

Iradimed Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Iradimed. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Iradimed position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Iradimed's important profitability drivers and their relationship over time.

Use Iradimed in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Iradimed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Iradimed will appreciate offsetting losses from the drop in the long position's value.

Iradimed Pair Trading

Iradimed Co Pair Trading Analysis

The ability to find closely correlated positions to Iradimed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Iradimed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Iradimed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Iradimed Co to buy it.
The correlation of Iradimed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Iradimed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Iradimed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Iradimed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Iradimed position

In addition to having Iradimed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Agriculture Thematic Idea Now

Agriculture
Agriculture Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Agriculture theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agriculture Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
To fully project Iradimed's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Iradimed at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Iradimed's income statement, its balance sheet, and the statement of cash flows.
Potential Iradimed investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Iradimed investors may work on each financial statement separately, they are all related. The changes in Iradimed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Iradimed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.